Nasdaq · Healthcare

Kymera Therapeutics, Inc. (KYMR)

As-reported financials and recent SEC filings for Kymera Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$39.2M

Net income

$-311.4M

Net margin

—

Diluted EPS

$-3.69

ROE

-19.7%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$39.2M	$47.1M	$78.6M	$46.8M	$72.8M
Gross profit	$0	$0	$0	$0	—
Operating income	$-349.4M	$-261.6M	$-165.5M	$-161.3M	$-100.5M
Net income	$-311.4M	$-223.9M	$-147.0M	$-154.8M	$-100.2M
Diluted EPS	$-3.69	$-2.98	$-2.52	$-2.87	$-2.09

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-07-02

4/A2026-07-02

42026-07-02

42026-07-02

42026-07-02

1442026-07-01

1442026-06-30

42026-06-30

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on KYMR

Search Kymera Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.